Oliver Wengert

TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis

Klaus‐Peter Wandinger, Jan D. Lünemann, Oliver Wengert et al. · The Lancet · 2003 · 206 citations

Life Sciences, Immunology, Neuroscience +17

Immune-Mediated Necrotizing Myopathy Is Characterized by a Specific Th1-M1 Polarized Immune Profile

Corinna Preuße, Hans H. Goebel, Josephin Held et al. · American Journal Of Pathology · 2012 · 119 citations · Full text

Veterinary Medicine, Immunology, Pathology +14

Proresolution Lipid Mediators in Multiple Sclerosis — Differential, Disease Severity-Dependent Synthesis — A Clinical Pilot Trial

Berit Rosche, Aaron B. Sullivan, Benedikt Brommer et al. · PLoS ONE · 2013 · 107 citations · Full text

Life Sciences, Neurology, Pharmacology +17

Neurosarcoidosis: Correlation of cerebrospinal fluid findings with diffuse leptomeningeal gadolinium enhancement on MRI and clinical disease activity

Oliver Wengert, E Rothenfußer-Korber, Boris Vollrath et al. · Journal of the Neurological Sciences · 2013 · 83 citations

Medicine, Neurology, Radiology +16

Multiple sclerosis: The elevated antibody response to Epstein–Barr virus primarily targets, but is not confined to, the glycine–alanine repeat of Epstein–Barr nuclear antigen-1

Klemens Ruprecht, Benjamin Wunderlich, René M. Gieß et al. · Journal of Neuroimmunology · 2014 · 45 citations

Life Sciences, Immunology, Pathology +12